losartan and mk 2206

losartan has been researched along with mk 2206 in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	1 (100.00)	2.80

Authors

Authors	Studies
Miao, FA; Xu, JG; Zhang, GH; Zhang, Y	1

Other Studies

1 other study(ies) available for losartan and mk 2206

Article	Year
Angiotensin II enhances the proliferation of Natural Killer/T-cell lymphoma cells via activating PI3K/Akt signaling pathway. Bioscience reports, 2020, 10-30, Volume: 40, Issue:10 Topics: Aged; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Cell Survival; Female; Heterocyclic Compounds, 3-Ring; Humans; Losartan; Lymph Nodes; Lymphoma, Extranodal NK-T-Cell; Male; Middle Aged; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Receptor, Angiotensin, Type 1; Signal Transduction; Wortmannin; Xenograft Model Antitumor Assays	2020

Article

Year

Angiotensin II enhances the proliferation of Natural Killer/T-cell lymphoma cells via activating PI3K/Akt signaling pathway.

Bioscience reports, 2020, 10-30, Volume: 40, Issue:10

Topics: Aged; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Cell Survival; Female; Heterocyclic Compounds, 3-Ring; Humans; Losartan; Lymph Nodes; Lymphoma, Extranodal NK-T-Cell; Male; Middle Aged; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Receptor, Angiotensin, Type 1; Signal Transduction; Wortmannin; Xenograft Model Antitumor Assays

2020